Core Viewpoint - ALK has entered a 4-year co-promotion agreement with ARS Pharmaceuticals to promote the neffy adrenaline nasal spray to US pediatricians, enhancing access to this life-saving treatment for children at risk of anaphylaxis [1][2][4]. Group 1: Agreement Details - The agreement allows ALK to co-promote neffy to approximately 9,000 pediatricians in the USA, who currently account for nearly 10% of all adrenaline auto-injector prescriptions in the country [1][2]. - ALK will establish a dedicated pediatric sales force of around 60 people to drive neffy sales in the US pediatric segment, supported by ARS Pharma's marketing efforts [3][4]. - The agreement builds on a previous strategic license agreement from November 2024, which granted ALK exclusive rights to commercialize neffy globally, excluding certain countries [5]. Group 2: Financial Implications - Under the co-promotion terms, ARS Pharma will cover most direct costs related to ALK's sales activities, and ALK will receive a performance-related revenue share based on net sales exceeding specific market share thresholds [6][8]. - The agreement is expected to contribute to ALK's revenue growth starting in 2025, although it will initially have a limited financial impact and a modest negative effect on earnings before interest and taxes (EBIT) [8][11]. - ALK's revenue and earnings outlook for 2025 remains unchanged despite this new agreement [8][11].